Literature DB >> 10510449

The effect of body temperature on myocardial protection conferred by ischaemic preconditioning or the selective adenosine A1 receptor agonist GR79236, in an anaesthetized rabbit model of myocardial ischaemia and reperfusion.

A Sheldrick1, K M Gray, G M Drew, J B Louttit.   

Abstract

1 The cardioprotective effect of N-[(1S, trans)-2-hydroxycyclopentyl]adenosine (GR79236), an adenosine A1 receptor agonist, was compared with that produced by ischaemic preconditioning in an anaesthetized rabbit model of myocardial ischaemia and reperfusion. In addition, we examined the effect of different body core temperatures on GR79236- or ischaemic preconditioning-induced cardioprotection when administered prior to ischaemia, and on cardioprotection induced by GR79236 administered 10 min prior to the onset of reperfusion. 2 When rabbits were subjected to 30 min occlusion of the left coronary artery, followed by 2 h reperfusion, GR79236 (3 x 10(-8) mol kg-1 i.v. (10.5 microg kg-1 i.v.)) or ischaemic preconditioning (5 min ischaemia followed by 5 min reperfusion), administered or applied 10 min prior to the occlusion, significantly limited the development of infarction. The cardioprotective effect of ischaemic preconditioning was significantly greater than that seen after administration of GR79236. Pre-treatment with the selective adenosine A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX, 3.3 x 10(-6) mol kg-1 (1 mg kg-1 i.v.)), prevented the cardioprotective effect of GR79236, but not that of ischaemic preconditioning. 3 Maintaining body core temperature at 38.5 degrees C rather than at 37.0 degrees C did not influence infarct size in control groups of rabbits, but reduced the cardioprotective effect of GR79236 when administered 10 min prior to occlusion or 10 min prior to the onset of reperfusion. The cardioprotective effect of ischaemic preconditioning was not temperature-dependent. 4 In conclusion, myocardial protection conferred by GR79236 in anaesthetized rabbits is mediated via adenosine A1 receptors. Myocardial protection can be conferred when GR79236 is administered before the onset of ischaemia or reperfusion, and is reduced when body core temperature is maintained at 38.5 degrees C rather than at 37.0 degrees C. In contrast, myocardial protection conferred by ischaemic preconditioning is not reduced by adenosine A1 receptor blockade, or by maintaining body core temperature at 38.5 degrees C rather than at 37.0 degrees C. These findings point to distinct differences in the mechanisms of induction of myocardial protection by adenosine A1 receptor agonist and ischaemic preconditioning. They also highlight the need for careful control of body core temperature when investigating the phenomenon of cardioprotection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510449      PMCID: PMC1571642          DOI: 10.1038/sj.bjp.0702799

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  Myocardial infarct size-Limiting effect of ischemic preconditioning: Its natural decay and the effect of repetitive preconditioning.

Authors:  T Miura; T Adachi; T Ogawa; T Iwamoto; A Tsuchida; O Iimur
Journal:  Cardiovasc Pathol       Date:  1992 Apr-Jun       Impact factor: 2.185

Review 2.  Adenosine and the anti-infarct effects of preconditioning.

Authors:  J M Downey; G S Liu; J D Thornton
Journal:  Cardiovasc Res       Date:  1993-01       Impact factor: 10.787

3.  Myocardial protection is lost before contractile function recovers from ischemic preconditioning.

Authors:  C E Murry; V J Richard; R B Jennings; K A Reimer
Journal:  Am J Physiol       Date:  1991-03

4.  Hypothermia extends the cardioprotection by ischaemic preconditioning to coronary artery occlusions of longer duration.

Authors:  M A van den Doel; B C Gho; S Y Duval; R G Schoemaker; D J Duncker; P D Verdouw
Journal:  Cardiovasc Res       Date:  1998-01       Impact factor: 10.787

5.  Adenosine receptor involvement in a delayed phase of myocardial protection 24 hours after ischemic preconditioning.

Authors:  G F Baxter; M S Marber; V C Patel; D M Yellon
Journal:  Circulation       Date:  1994-12       Impact factor: 29.690

6.  Cardiac stress protein elevation 24 hours after brief ischemia or heat stress is associated with resistance to myocardial infarction.

Authors:  M S Marber; D S Latchman; J M Walker; D M Yellon
Journal:  Circulation       Date:  1993-09       Impact factor: 29.690

7.  Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor.

Authors:  Q Y Zhou; C Li; M E Olah; R A Johnson; G L Stiles; O Civelli
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205

8.  Role of myocardial ATP-sensitive potassium channels in mediating preconditioning in the dog heart and their possible interaction with adenosine A1-receptors.

Authors:  G J Grover; P G Sleph; S Dzwonczyk
Journal:  Circulation       Date:  1992-10       Impact factor: 29.690

9.  Evidence that the adenosine A3 receptor may mediate the protection afforded by preconditioning in the isolated rabbit heart.

Authors:  G S Liu; S C Richards; R A Olsson; K Mullane; R S Walsh; J M Downey
Journal:  Cardiovasc Res       Date:  1994-07       Impact factor: 10.787

10.  "Normothermic range" temperature affects myocardial infarct size.

Authors:  G L Chien; R A Wolff; R F Davis; D M van Winkle
Journal:  Cardiovasc Res       Date:  1994-07       Impact factor: 10.787

View more
  2 in total

1.  Does a selective adenosine A(1) receptor agonist protect against exercise induced ischaemia in patients with coronary artery disease?

Authors:  A D Kelion; T P Webb; M A Gardner; O J Ormerod; G L Shepherd; A P Banning
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

2.  Interaction between neuronal nitric oxide synthase signaling and temperature influences sarcoplasmic reticulum calcium leak: role of nitroso-redox balance.

Authors:  Raul A Dulce; Vera Mayo; Erika B Rangel; Wayne Balkan; Joshua M Hare
Journal:  Circ Res       Date:  2014-10-17       Impact factor: 17.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.